It has been observed that Calmodulin-dependent kinase II (CaMKII) is active in the bronchial epithelium of asthmatic patients, and the CaMKII inhibitor peptide CaMKII has shown potential in treating allergic asthma in mice (Morris et al. 2017). Here, CAMK2G is linked to allergic asthma.